Contraindications for Teneligliptin
Teneligliptin has no absolute contraindications documented in the available evidence, but should be avoided in patients with known hypersensitivity to the drug or any of its inactive ingredients.
Key Clinical Considerations
The FDA drug label evidence 1 provided appears to be mislabeled and actually describes acetaminophen rather than teneligliptin, so cannot be used for contraindication guidance. However, based on the DPP-4 inhibitor class characteristics and teneligliptin-specific research, the following clinical situations warrant careful consideration:
Situations Requiring Caution (Not Absolute Contraindications)
Pancreatitis Risk:
- Do not initiate teneligliptin in patients at high risk for pancreatitis
- Discontinue immediately if pancreatitis is suspected
- This aligns with the broader DPP-4 inhibitor class guidance 2
QT Prolongation:
- Exercise caution in patients prone to QT prolongation 3
- This is a teneligliptin-specific consideration not universally applicable to all DPP-4 inhibitors
Joint Pain:
- Monitor for severe and debilitating arthralgia (postmarketing concern for DPP-4 inhibitor class)
- Consider discontinuation if debilitating symptoms develop and other treatment options are feasible 2
Bullous Pemphigoid:
- Discontinue if this rare skin condition is suspected 2
Renal Impairment - A Major Advantage
Unlike other DPP-4 inhibitors, teneligliptin requires no dose adjustment in renal impairment 3. This is because its metabolites are eliminated via both renal and hepatic routes, making it particularly advantageous compared to sitagliptin, saxagliptin, and alogliptin, which all require dose adjustments based on kidney function 2.
Pregnancy and Breastfeeding
The evidence does not provide specific contraindications for pregnancy or breastfeeding with teneligliptin. Following general DPP-4 inhibitor class guidance, consultation with healthcare providers is warranted in these situations.
Hypersensitivity
As with any medication, known hypersensitivity or allergic reactions to teneligliptin or its components would constitute a contraindication.
Clinical Bottom Line
Teneligliptin demonstrates a favorable safety profile with no absolute contraindications beyond hypersensitivity. Its dual hepatic-renal elimination pathway makes it particularly useful in patients with renal impairment where other DPP-4 inhibitors would require dose adjustment 3, 4. The main clinical concerns mirror the broader DPP-4 inhibitor class (pancreatitis, joint pain, bullous pemphigoid) with the additional teneligliptin-specific consideration of QT prolongation risk.